Latest from research and the clinic.
New trial results, patient questions answered, India updates, and plain-language commentary on Lutetium therapy. Updated weekly. Reviewed by medical oncologists.
What Happens to Your PSA Levels During Lu-177 PSMA Therapy — When to Expect Changes and What They Mean for Your Treatment
Your PSA level is one of the key signals doctors use to judge whether Lu-177 PSMA therapy is working. This article explains when PSA changes typically appear, what a decline or rise may mean for your prognosis, and how doctors interpret PSA alongside imaging and other markers throughout treatment.
What Should I Do to Prepare for My First Lu-177 DOTATATE Infusion If My Neuroendocrine Tumor Has Metastasized?
Your first Lu-177 DOTATATE infusion involves more than just showing up. From pausing somatostatin analogs to following radiation safety steps at home, here is a practical preparation guide for patients with metastatic neuroendocrine tumors.
If My Insurance Won't Cover Lu-177 PSMA Therapy for PSMA-Positive Prostate Cancer, What Are My Realistic Financial Options?
An insurance denial for Lu-177 PSMA therapy is not the end of the road. This guide explains your realistic financial options — from formal appeals and manufacturer assistance to clinical trials and international treatment — in plain, practical language.
Can I Get Lu-177 DOTATATE If I Have Kidney Disease or Diabetes? What Comorbidities Mean for Treatment Eligibility
Kidney disease and diabetes do not automatically rule out Lu-177 DOTATATE for neuroendocrine tumors. Learn what numbers and conditions your care team actually reviews — and what may still give you a path forward.
If My Carcinoid Tumor Shrinks on Lu-177 DOTATATE, Can I Have Surgery Afterward — What the Evidence Says About Combining DOTATATE Response with Surgical Resection
If Lu-177 DOTATATE is shrinking your carcinoid tumor, surgery may become possible for some patients. Here is what the current evidence says about combining PRRT response with surgical resection — and how to ask the right questions of your care team.
How Long Until Lu-177 PSMA Shrinks Your Tumor — What Response Timelines and Scans Show About Treatment Success
Men with advanced prostate cancer often wonder how soon Lu-177 PSMA therapy will show results. This article explains what PSA trends, PSMA PET scans, and clinical trial data tell us about how and when treatment response typically appears.
If My Bone Metastases Are in My Spine or Near My Spinal Cord, Is Lu-177 PSMA Safe — What the Evidence Says About Lesion Location and Toxicity
Many men with spinal bone metastases wonder whether Lu-177 PSMA therapy is safe when cancer sits close to the spinal cord. Here is what the clinical evidence says about lesion location, bone marrow risk, and who may still qualify.
Will I Lose My Hair During Lu-177 DOTATATE for My GEP-NET — What the Evidence Says and What Patients Actually Experience
Hair loss is one of the first worries patients have about Lu-177 DOTATATE therapy — but the clinical evidence and patient reports tell a very different story from chemotherapy. Learn what the data actually shows and what most GEP-NET patients experience.
What Happens to Your Bone Density and Fracture Risk During Lu-177 PSMA Therapy — How to Protect Your Skeleton During Treatment
When you have metastatic castration-resistant prostate cancer, your bones face two threats at once — cancer spread and hormone therapy-related bone loss. This guide explains how Lu-177 PSMA therapy affects your skeleton and what steps can help protect your bones during treatment.
What Happens the Week After Your Lu-177 PSMA Infusion? Can You Return to Work, Exercise, and Normal Activities?
The first week after a Lu-177 PSMA infusion involves managing radiation safety at home, watching for common side effects, and making thoughtful decisions about work and activity. This guide explains what to expect — day by day — and when it is realistically safe to return to normal life.
If My Prostate Cancer Is PSMA-Positive and Hormone-Sensitive, Can I Get Lu-177 PSMA Therapy Before It Becomes Castration-Resistant — and What Does the Evidence Say About Early Access?
Most men with PSMA-positive prostate cancer wonder whether they have to wait for castration resistance before they can access Lu-177 PSMA therapy. Here is what current approvals say — and what emerging trial evidence suggests about earlier access.
How Long Can Lu-177 DOTATATE Keep My Carcinoid Tumor Stable? What Progression-Free Survival Data Says About Your Timeline
The landmark NETTER-1 trial found that more than half of midgut carcinoid tumor patients had not progressed at 20 months on Lu-177 DOTATATE. Here is what the progression-free survival data — from clinical trials and real-world studies — may mean for your personal timeline.
How we choose what to write about
We focus on three kinds of content:
- Trial results that change practice - plain-language summaries of new evidence, with honest framing of what it does and doesn't mean
- Patient questions we hear repeatedly - taking the most common navigator-conversation questions and answering them publicly
- India updates - new centers, new approvals, new policies that affect Indian and India-bound patients
Every clinical post is reviewed by an oncologist or nuclear medicine physician before publication.
Have a specific question about your situation?
A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.
Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.